The global Hematologic Malignancies market size is expected to be worth around US$ 95.8 billion by 2030, according to a new report by Vision Research Reports.
The global Hematologic Malignancies market size was valued at US$ 45.6 billion in 2020 and is anticipated to grow at a CAGR of 20.48 % during forecast period 2021 to 2030.
Increasing incidence of hematologic malignancies and presence of a strong product pipeline are estimated to boost the market. Moreover, increasing number of mergers and acquisitions are also expected to accelerate growth.
Furthermore, governments of developing countries are spending more on healthcare and on improving healthcare infrastructure. This is likely to reduce out-of-pocket expenditure for patients. which is considered as one of the major factors driving the hematologic malignancies market.
Recently it has been seen that the government sources are taking an initiative in funding the institutes for breakthrough oncology research. This is a major growth driver for the market as it will support the institutes to conduct their research on a larger-scale without any financial constraints. Federal government funding for research in oncology has led to a substantial development in cancer detection, prevention, diagnosis, treatment and quality of life for patients. Due to the advancement in cancer research, more patients with cancer are being successfully treated. The increasing investment in cancer research is expected to boost the growth of market during forecast period
Based on type, the market is categorized into leukemia, lymphoma, and multiple myeloma. Leukemia is further categorized into acute lymphocytic, chronic lymphocytic, acute myeloid, and chronic myeloid leukemia. Acute lymphocytic leukemia is the most prevalent type of leukemia, which accounted for 56% of cases in adolescents and 80% in children from 2016 to 2017.
Leukemia was the largest segment in 2016, owing to the presence of best-selling brands like Rituxan, Imbruvica, and Glivec, which are reported to be some of the highest revenue-generating oncology drugs. Acute myeloid is expected to witness the fastest growth over the forecast period due to the presence of a strong product pipeline and its expected commercialization.
The therapy segment is further categorized into chemotherapy, radiotherapy, immunotherapy, and stem cell transplantation. Chemotherapy was the largest segment in 2016, as it is the first line of treatment. For most types of blood cancer, chemotherapy is the usual treatment and a particular drug or combination of drugs are used, based on the type of cancer.
Immunotherapy is estimated to witness the fastest growth of 11.2% over the forecast. Effectiveness of the treatment, lower adverse effects, and presence of brands like Rituxan, Revlimid, Mabthera, Gazyva, and Arzerra are responsible for the growth of this segment.
North America dominated the hematologic malignancy market, and it held the market share of over 39% in 2016. Presence of key players, established healthcare infrastructure, and availability of branded drugs are some of the factors responsible for its large share. Besides, favorable government initiatives and increase in number of research collaborations are some of the drivers expected to accelerate the market growth.
Asia Pacific is estimated to be the fastest-growing over the forecast period with CAGR of around 12.5%, owing to the increase in healthcare expenditure, rising awareness about early diagnosis, high unmet clinical needs of patients, and availability of effective treatment in emerging countries, such as China and India.
Pfizer, Inc.; F. Hoffmann-LA Roche ltd; Sanofi-Aventis; Bristol-Myers Squibb Company; AbbVie, Inc.; Novartis AG; GlaxoSmithKline PLC; Celgene Corporation; Johnson & Johnson Services, Inc.; and Takeda Pharmaceutical Company Limited.
Acute Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Acute Myeloid Leukemia
Chronic Myeloid Leukemia
Stem Cell Transplantation
Middle East & Africa
The Hematologic Malignancies market research report covers definition, classification, product classification, product application, development trend, product technology, competitive landscape, industrial chain structure, industry overview, national policy and planning analysis of the industry, the latest dynamic analysis, etc., and also includes major. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level.
The report provides size (in terms of volume and value) of Hematologic Malignancies market for the base year 2020 and the forecast between 2021 and 2030. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
This report focuses on the global Hematologic Malignancies market status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hematologic Malignancies market development in United States, Europe and China.
It is pertinent to consider that in a volatile global economy, we haven’t just conducted Hematologic Malignancies market forecasts in terms of CAGR, but also studied the market based on key parameters, including Year-on-Year (Y-o-Y) growth, to comprehend the certainty of the market and to find and present the lucrative opportunities in market.
In terms of production side, this report researches the Hematologic Malignancies capacity, production, value, ex-factory price, growth rate, market share for major manufacturers, regions (or countries) and type.
In terms of consumption side, this report focuses on the consumption of Hematologic Malignancies by regions (countries) and application.
Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of production analysis, the authors of the report have provided reliable estimations and calculations for global revenue and volume by Type segment of the global Hematologic Malignancies market. These figures have been provided in terms of both revenue and volume for the period 2017 to 2030. Additionally, the report provides accurate figures for production by region in terms of revenue as well as volume for the same period. The report also includes production capacity statistics for the same period.
With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major Hematologic Malignancies market companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of Hematologic Malignancies market upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of market and consumption, major regions and Consumption, major Chinese producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The research in this report also includes product parameters, production process, cost structure, and data information classified by region, technology and application. Finally, the paper model new project SWOT analysis and investment feasibility study of the case model.
Overall, this is an in-depth research report specifically for the Hematologic Malignancies industry. The research center uses an objective and fair way to conduct an in-depth analysis of the development trend of the industry, providing support and evidence for customer competition analysis, development planning, and investment decision-making. In the course of operation, the project has received support and assistance from technicians and marketing personnel in various links of the industry chain.
The Hematologic Malignancies market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to Hematologic Malignancies market.
Prominent players in the market are predicted to face tough competition from the new entrants. However, some of the key players are targeting to acquire the startup companies in order to maintain their dominance in the global market. For a detailed analysis of key companies, their strengths, weaknesses, threats, and opportunities are measured in the report by using industry-standard tools such as the SWOT analysis. Regional coverage of key companies is covered in the report to measure their dominance. Key manufacturers of Hematologic Malignancies market are focusing on introducing new products to meet the needs of the patrons. The feasibility of new products is also measured by using industry-standard tools.
Key companies are increasing their investments in research and development activities for the discovery of new products. There has also been a rise in the government funding for the introduction of new Hematologic Malignancies market. These factors have benefited the growth of the global market for Hematologic Malignancies. Going forward, key companies are predicted to benefit from the new product launches and the adoption of technological advancements. Technical advancements have benefited many industries and the global industry is not an exception.
New product launches and the expansion of already existing business are predicted to benefit the key players in maintaining their dominance in the global market for Hematologic Malignancies. The global market is segmented on the basis of region, application, en-users and product type. Based on region, the market is divided into North America, Europe, Asia-Pacific, Latin America and Middle East and Africa (MEA).
In this study, the years considered to estimate the market size of Hematologic Malignancies are as follows:
Reasons to Purchase this Report:
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value USD Million and volume Units Million data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
This research study involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.
Market Size Estimation
Top-down and bottom-up approaches are used to estimate and validate the global market size for company, regional division, product type and application (end users).
The market estimations in this report are based on the selling price (excluding any discounts provided by the manufacturer, distributor, wholesaler or traders). Market share analysis, assigned to each of the segments and regions are achieved through product utilization rate and average selling price.
Major manufacturers & their revenues, percentage splits, market shares, growth rates and breakdowns of the product markets are determined through secondary sources and verified through the primary sources.
All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or others factors are accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from Vision Research Reports and presented in this report.
Market Breakdown and Data Triangulation
After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation. Extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report.
Secondary Sources occupies approximately 25% of data sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on. This research study includes secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; investor presentations; and SEC filings of companies.
In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers, etc.
The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
The study objectives of this report are:
To strategically profile the key players and comprehensively analyze their growth strategies.